Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception (SHERLOCK)

This study will collect, annotate, and sequence biospecimens (blood, tissue, urine, saliva and surgery drainage) from patients across different cancer types to detect molecular residual disease (MRD). Imaging scans and clinical data will also be gathered. This will allow for early cancer interception, and hopefully prolong relapse-free survival across tumor types. Results of ctDNA testing will be provided for clinical decisions and to determine eligibility for other linked interventional interception therapeutic studies, each of which will have a separate protocol.

NCT Number	NCT07524114
Lead Sponsor	University Health Network, Toronto Collaborators: Princess Margaret Hospital, Canada
Conditions	Breast Cancer, Lung Cancer, Melanoma, Gynecologic Cancer, Genitourinary Cancer, Pancreatobiliary Cancer, Gastrointestinal Cancer, Head and Neck Cancer +2 more
Enrollment	7,000 participants
Start Date	2026-03-31
Primary Completion	2031-03-31 (estimated)
Study Completion	2031-03-31 (estimated)
Updated on ClinicalTrials.gov	2026-05-11